Structured evidence table for Probiotic Skin Barrier Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Probiotic Skin Barrier Randomized Trial | This review adopts a systems-level perspective to synthesize emerging evidence on probiotic-driven gut–brain, gut–skin, gut–oral, and metabolic interactions, emphasizing shared mechanisms rather than isolated clinical outcomes. | 3 | Zalila-Kolsi Imen (2026) | Probiotics and the Human Microbiome: Classical Functions, Emerging Systemic Roles, and Future Therapeutic Frontiers |
| Probiotic Skin Barrier Randomized Trial | In parallel, advances in encapsulation and delivery technologies have improved probiotic survival during gastrointestinal transit, thereby enhancing their functional efficacy within the gut. | 3 | Zalila-Kolsi Imen (2026) | Probiotics and the Human Microbiome: Classical Functions, Emerging Systemic Roles, and Future Therapeutic Frontiers |
| Probiotic Skin Barrier Randomized Trial | rhamnosus 14 16 Functionally, experimental and clinical studies indicate that strain-specificspecies, such as,, and, regulate gut motility and carbohydrate metabolism, contributing to improved lactose digestion and alleviation of constipation and bloating []. | 3 | Zalila-Kolsi Imen (2026) | Probiotics and the Human Microbiome: Classical Functions, Emerging Systemic Roles, and Future Therapeutic Frontiers |
| Probiotic Skin Barrier Randomized Trial | 1 2 3 4 5 Lactobacillus Bifidobacterium Enterococcus Streptococcus Saccharomyces boulardii, The term “probiotics,” which comes from the Greek word “for life,” refers to live microorganisms that, when given in sufficient quantities, promote the host’s health []. | 3 | Zalila-Kolsi Imen (2026) | Probiotics and the Human Microbiome: Classical Functions, Emerging Systemic Roles, and Future Therapeutic Frontiers |
| Probiotic Skin Barrier Randomized Trial | Elevated reactive oxygen species (ROS) also play a key role, as increased ROS levels are found in patients with rosacea []. | 4 | Muacevic Alexander (2026) | The Role of Biotics in Rosacea: A Narrative Review |
| Probiotic Skin Barrier Randomized Trial | Mendelian randomization studies have linked certain bacterial taxa, including uncategorized[] andspecies [], to an increased risk of rosacea, while other taxa appear to confer a protective effect []. | 4 | Muacevic Alexander (2026) | The Role of Biotics in Rosacea: A Narrative Review |
| Probiotic Skin Barrier Randomized Trial | Although these studies provide limited mechanistic insight, they strengthen the evidence that microbial composition influences disease risk and expression. | 4 | Muacevic Alexander (2026) | The Role of Biotics in Rosacea: A Narrative Review |
| Probiotic Skin Barrier Randomized Trial | General features of rosacea 1 2 4 Rosacea is a chronic inflammatory skin condition affecting about 5.5% of adults, mainly aged 30-50. | 4 | Muacevic Alexander (2026) | The Role of Biotics in Rosacea: A Narrative Review |
Source documents